DentalEZ Alabama, Inc.
$5.9K 13 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
ReShape Lifesciences Inc.
ReShape Lifesciences Inc. reported $5,842.88 across General Payments, Research, and Ownership to 15 physicians and teaching hospitals across 15 transactions.
- $5.8K
- All-tracks total
- 15
- Transactions
- 15
- Recipients
- −$34.2K
- General Payments vs PY2023
ReShape Lifesciences Inc. reported $5,842.88 across all CMS Open Payments tracks (General + Research + Ownership) to 15 physicians and teaching hospitals in Program Year 2024 - ranking #1698 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $5,842.88, averaging $389.53 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer reshape-lifesciences-inc ReShape Lifesciences Inc.
$5.8K · #1698/1,925 · 0.0% industry · PY2024
- TOT $5.8K
- RANK #1698
- SHARE 0.0%
- TXN 15
- RCP 15
- CAT 2
- GEN $5.8K
- ΔGEN −$34.2K
- TOP1 73.4%
- PY 2024
Volume peers
Nearest volume peer: DentalEZ Alabama, Inc. ($5.9K)
ReShape Lifesciences Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
ReShape Lifesciences Inc.'s CMS-reported General Payments decreased by $34.2K (−85.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: RESHAPE LIFESCIENCES INC.PY2023: RESHAPE LIFESCIENCES INC.PY2024: ReShape Lifesciences Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $40,057.06
- PY2024
- $5,842.88
What the Data Shows for ReShape Lifesciences Inc.
In Program Year 2024, ReShape Lifesciences Inc. reported $5,842.88 in payments to 15 physicians and teaching hospitals across 15 individual transactions, an average of $389.53 per transaction and $389.53 per recipient. That total places ReShape Lifesciences Inc. at rank #1698 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
"Consulting Fee" leads the 2-category general-payment breakdown below at $5.6K (95.8% of General Payments, 5 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads ReShape Lifesciences Inc.'s 2-category general-payment breakdown at $5.6K, 95.8% of the reported total.
How ReShape Lifesciences Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $5.6K | 5 | 95.8% |
| Food and Beverage | $242.88 | 10 | 4.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $5,701.74 (97.6%) of $5,842.88 in this company's General Payments records across 12 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for ReShape Lifesciences Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Christine Fielding
$4,287.50 across 4 reported transactions
- 2
Vafa Shayani
$1,312.50 across 1 reported transactions
- 3
Jeffrey Allen
$39.80 across 1 reported transactions
- 4
Jeffrey Holloway
$30.97 across 1 reported transactions
- 5
Amber Schulze
$30.97 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as ReShape Lifesciences Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about ReShape Lifesciences Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with ReShape Lifesciences Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Perfuze Inc
$5.8K 5 recipients
Compare payment profiles
Escala Medical Inc.
$6.0K 52 recipients
Compare payment profiles
Dunamis Medical, LLC
$6.0K 48 recipients
Compare payment profiles
Bridge to Life Ltd
$5.6K 9 recipients
Compare payment profiles
Rare Disease Therapeutics, Inc.
$5.6K 104 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.